title: [The use of Capoten in systemic scleroderma].
abstract: Experience gained with the use of captopril has been summarized in 5 patients with sclerodermic renal crisis (true sclerodermic kidney) as well as the results of the double blind clinical trial of captopril in 16 patients with Raynaud's syndrome. Captopril given for a long time in the dose 75-150 mg to the patients with true sclerodermic kidney turned out effective which showed up by a decline and stabilization of arterial pressure, decrease of the intensity of azotemia and headaches, and stabilization of renal function. No convincing data have been obtained, that may confirm a beneficial effect of captopril on Raynaud's syndrome. The drug was applied in a dose of 37.5 mg for 2 weeks.
authors.forename: N G
authors.initials: NG
authors.lastname: Guseva
authors.forename: N V
authors.initials: NV
authors.lastname: Anikina
authors.forename: A B
authors.initials: AB
authors.lastname: Shcherbakov
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002216:Captopril / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000150:complications / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*
chemical_list: D002216:Captopril
vernacular_title: Primenenie kapotena pri sistemnoĭ sklerodermii.